Shivani Singh

Shivani Singh

Durban, South Africa
T: +27 31 109 1150
  • Overview
  • Experience


Shivani Singh is a consultant in our Corporate Department and a member of the Mergers & Acquisitions practice. Shivani has multi-jurisdictional mergers and acquisitions experience across South Africa, Australia, USA and Europe. She has gained senior commercial legal expertise in a listed company in areas including licensing, pharmaceutical development, manufacturing, supply, distribution, procurement, technology, marketing and sales, service level agreements and transition agreements.

Having worked extensively in pharmaceutical manufacturing, Shivani has served as a member of the site leadership council for a listed pharmaceutical company and has acquired a robust understanding of the manufacturing value chain.

Shivani holds an LLB degree (magna cum laude) from the University of KwaZulu Natal, a certificate in management development from GIBS, a certificate in EU law from Kings College (London) and was admitted to the High Court of South Africa as an attorney and notary public in 2004.

Specialist Services

Relevant Experience

* includes experience gained prior to joining Bowmans

  • Legal lead for the technology transfer, IP licensing and commercial manufacture by a South African company of a viral vector COVID-19 vaccine, for worldwide supply. This included the sourcing agreements for vaccine componentry. Deal value: approx. EUR 135 million.
  • Legal lead for a pharmaceutical company on the asset purchase agreement, distribution, and technical agreements for the divestment of a portfolio of thrombosis products in Europe. Deal value: EUR 641.9 million.
  • Legal lead for a Mauritius based company in its divestment of rights to a pharmaceutical product in Europe. Deal value: USD 15 million.
  • Legal lead for a significant procurement alignment project across active pharmaceutical ingredient (API) and finished dose manufacturing sites located in South Africa, Netherlands, Germany and France.
  • Legal lead for a pharmaceutical company in its exercise of an option and acquisition of worldwide rights (excluding USA) to a basket of anaesthetic products. Deal value: USD 555 million.